Henan Lingrui Pharmaceutical Co Ltd
SSE:600285
Wall Street
Price Targets
Price Targets Summary
Henan Lingrui Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for Henan Lingrui Pharmaceutical Co Ltd is 11.83 CNY .
Price Targets
Revenue
Forecast
Revenue Estimate
Henan Lingrui Pharmaceutical Co Ltd
For the last 8 years the compound annual growth rate for Henan Lingrui Pharmaceutical Co Ltd's revenue is 17%. The projected CAGR for the next 3 years is 14%.
Operating Income
Forecast
Operating Income Estimate
Henan Lingrui Pharmaceutical Co Ltd
For the last 8 years the compound annual growth rate for Henan Lingrui Pharmaceutical Co Ltd's operating income is 28%. The projected CAGR for the next 5 years is -9%.
Net Income
Forecast
Net Income Estimate
Henan Lingrui Pharmaceutical Co Ltd
For the last 8 years the compound annual growth rate for Henan Lingrui Pharmaceutical Co Ltd's net income is 25%. The projected CAGR for the next 3 years is 18%.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is Henan Lingrui Pharmaceutical Co Ltd's stock price target?
Price Target
11.83
CNY
According to Wall Street analysts, the average 1-year price target for Henan Lingrui Pharmaceutical Co Ltd is 11.83 CNY .
What is Henan Lingrui Pharmaceutical Co Ltd's Revenue forecast?
Projected CAGR
14%
For the last 8 years the compound annual growth rate for Henan Lingrui Pharmaceutical Co Ltd's revenue is 17%. The projected CAGR for the next 3 years is 14%.
What is Henan Lingrui Pharmaceutical Co Ltd's Operating Income forecast?
Projected CAGR
-9%
For the last 8 years the compound annual growth rate for Henan Lingrui Pharmaceutical Co Ltd's operating income is 28%. The projected CAGR for the next 5 years is -9%.
What is Henan Lingrui Pharmaceutical Co Ltd's Net Income forecast?
Projected CAGR
18%
For the last 8 years the compound annual growth rate for Henan Lingrui Pharmaceutical Co Ltd's net income is 25%. The projected CAGR for the next 3 years is 18%.